BRPI0411929A - compostos de piperazino-(1-sulfonilmetil-alquil)n-hidróxiformami da n-(4 ' -substituìdos) como inibidores de metaloproteinase - Google Patents

compostos de piperazino-(1-sulfonilmetil-alquil)n-hidróxiformami da n-(4 ' -substituìdos) como inibidores de metaloproteinase

Info

Publication number
BRPI0411929A
BRPI0411929A BRPI0411929-0A BRPI0411929A BRPI0411929A BR PI0411929 A BRPI0411929 A BR PI0411929A BR PI0411929 A BRPI0411929 A BR PI0411929A BR PI0411929 A BRPI0411929 A BR PI0411929A
Authority
BR
Brazil
Prior art keywords
alkyl
compounds
ring
aryl
heteroaryl
Prior art date
Application number
BRPI0411929-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Maurice Finlay
Raymond Verschoyle
David Waterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0411929(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0411929A publication Critical patent/BRPI0411929A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
BRPI0411929-0A 2003-06-27 2004-06-23 compostos de piperazino-(1-sulfonilmetil-alquil)n-hidróxiformami da n-(4 ' -substituìdos) como inibidores de metaloproteinase BRPI0411929A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds
PCT/GB2004/002702 WO2005000822A1 (en) 2003-06-27 2004-06-23 N-{‘4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0411929A true BRPI0411929A (pt) 2006-08-15

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411929-0A BRPI0411929A (pt) 2003-06-27 2004-06-23 compostos de piperazino-(1-sulfonilmetil-alquil)n-hidróxiformami da n-(4 ' -substituìdos) como inibidores de metaloproteinase

Country Status (33)

Country Link
US (1) US7485644B2 (OSRAM)
EP (1) EP1644340B1 (OSRAM)
JP (1) JP4701167B2 (OSRAM)
KR (1) KR20060026440A (OSRAM)
CN (2) CN102229589A (OSRAM)
AR (1) AR044931A1 (OSRAM)
AT (1) ATE414063T1 (OSRAM)
AU (1) AU2004251104B2 (OSRAM)
BR (1) BRPI0411929A (OSRAM)
CA (1) CA2529468A1 (OSRAM)
CO (1) CO5650254A2 (OSRAM)
CY (1) CY1108757T1 (OSRAM)
DE (1) DE602004017733D1 (OSRAM)
DK (1) DK1644340T3 (OSRAM)
ES (1) ES2315675T3 (OSRAM)
HR (1) HRP20090009T3 (OSRAM)
IL (1) IL172615A0 (OSRAM)
IS (1) IS8257A (OSRAM)
MX (1) MXPA05013460A (OSRAM)
MY (1) MY138680A (OSRAM)
NO (1) NO20060444L (OSRAM)
NZ (1) NZ544208A (OSRAM)
PL (1) PL1644340T3 (OSRAM)
PT (1) PT1644340E (OSRAM)
RU (1) RU2351595C2 (OSRAM)
SA (1) SA04250224B1 (OSRAM)
SE (1) SE0301922D0 (OSRAM)
SI (1) SI1644340T1 (OSRAM)
TW (1) TW200524898A (OSRAM)
UA (1) UA81491C2 (OSRAM)
UY (1) UY28387A1 (OSRAM)
WO (1) WO2005000822A1 (OSRAM)
ZA (1) ZA200510458B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
RS52229B (sr) * 2005-10-26 2012-10-31 Merck Serono Sa. Derivati sulfonamida i njihova upotreba za modulaciju metaloproteinaza
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
KR101822444B1 (ko) * 2010-07-08 2018-01-26 가켄 세이야쿠 가부시키가이샤 N-히드록시포름아미드 유도체 및 그를 함유하는 의약

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200418B1 (pl) * 1998-01-30 2009-01-30 Darwin Discovery Ltd Pochodna N-hydroksyformamidu, zawierający ją środek farmaceutyczny i jej zastosowanie
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
KR20020005769A (ko) * 1999-06-04 2002-01-17 다비드 에 질레스 메탈로프로테이나제의 억제제
MXPA02008111A (es) * 2000-02-21 2002-11-29 Astrazeneca Ab N-hidroxiformamidas substituidas con piperidina y piperazina como inhibidores de metaloproteinasas.
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
BR0309671A (pt) * 2002-04-25 2005-05-03 Pharmacia Corp ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease
JP2006527754A (ja) * 2003-06-19 2006-12-07 セルテック アール アンド ディ リミテッド Cd23分断阻害物質としてのヒドロキサム酸スルホンアミド

Also Published As

Publication number Publication date
US20070197542A1 (en) 2007-08-23
PT1644340E (pt) 2009-01-02
RU2351595C2 (ru) 2009-04-10
IL172615A0 (en) 2006-04-10
DE602004017733D1 (de) 2008-12-24
CN102229589A (zh) 2011-11-02
SE0301922D0 (sv) 2003-06-27
TW200524898A (en) 2005-08-01
ATE414063T1 (de) 2008-11-15
NO20060444L (no) 2006-03-22
ZA200510458B (en) 2007-03-28
HK1086835A1 (en) 2006-09-29
CA2529468A1 (en) 2005-01-06
SI1644340T1 (sl) 2009-02-28
CY1108757T1 (el) 2014-04-09
AU2004251104B2 (en) 2008-05-08
MXPA05013460A (es) 2006-03-09
PL1644340T3 (pl) 2009-04-30
JP4701167B2 (ja) 2011-06-15
CO5650254A2 (es) 2006-06-30
MY138680A (en) 2009-07-31
WO2005000822A1 (en) 2005-01-06
CN1812974A (zh) 2006-08-02
CN1812974B (zh) 2011-06-29
ES2315675T3 (es) 2009-04-01
JP2007516164A (ja) 2007-06-21
AR044931A1 (es) 2005-10-12
IS8257A (is) 2006-01-23
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
DK1644340T3 (da) 2009-02-02
UY28387A1 (es) 2005-01-31
EP1644340B1 (en) 2008-11-12
RU2005141058A (ru) 2006-07-27
HRP20090009T3 (en) 2009-02-28
AU2004251104A1 (en) 2005-01-06
UA81491C2 (en) 2008-01-10
EP1644340A1 (en) 2006-04-12
KR20060026440A (ko) 2006-03-23
US7485644B2 (en) 2009-02-03

Similar Documents

Publication Publication Date Title
ECSP23095485A (es) N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
BR0012697A (pt) Inibidores da diferenciação de th2
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
BR0210874A (pt) Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso
BR0010520A (pt) Novos compostos farmaceuticamente ativos
ECSP066667A (es) Derivados de ciclohexano espirociclicos
CY1106166T1 (el) Παραγωγα κουιναζολινης ως αναστολεις vegf.
BRPI0409227C1 (pt) composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
BRPI0509307A (pt) compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
CY1112084T1 (el) Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3
BRPI0413616B1 (pt) 2,4-pirimidinadiaminas, seus usos, e composição farmacêutica
DK1206467T3 (da) N-heterocykliske derivater som NOS-inhibitorer
BR0313297A (pt) 6-alcóxi-pirido-pirimidinas como inibidores de p-38 map cinase
PA8609201A1 (es) Piridinonas sustituidas
BR112012033770A2 (pt) novo derivado de nicotinamida ou sal do mesmo
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0512985A (pt) derivados de 3-carbamoil-2-piridona
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
PE20020566A1 (es) DERIVADOS DE FENILACETAMIDO-PIRAZOLES COMO INHIBIDORES DE LA cdk/CICLINA QUINASA
BR112021018692A2 (pt) 1,1-dióxido de isotiazolidina e 1,4-butanossultona contendo derivados de rapamicina e usos dos mesmos
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: ARQUIVAMENTO DEFINITIVO

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2293 DE 16/12/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.